- Conditions
- Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
- Interventions
- somatropin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 22,960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2016
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 180
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Achondroplasia
- Interventions
- Recifercept
- Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Months to 10 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Growth Hormone Deficiency
- Interventions
- Somatropin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1998
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Achondroplasia
- Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 0 Years to 32 Months
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Oakland, California • Baltimore, Maryland • Madison, Wisconsin
- Conditions
- Loss of Chromosome 18q, Growth Hormone Deficiency
- Interventions
- Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, Neuropsychological Testing
- Drug · Procedure
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Achondroplasia
- Interventions
- BMN 111, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 11
- States / cities
- Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
- Conditions
- Growth Hormone Deficiency, Traumatic Brain Injury
- Interventions
- Recombinant human growth hormone
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 2
- States / cities
- Galveston, Texas
- Conditions
- Growth Hormone Deficiency
- Interventions
- GHRH/arginine stimulation testing
- Procedure
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Hypochondroplasia
- Interventions
- Not listed
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 30 Months to 16 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders
- Interventions
- glucagon stimulation test and insulin tolerance test
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Cleveland, Ohio • Portland, Oregon + 1 more
- Conditions
- Congenital Hypothyroidism
- Interventions
- Levothyroxine, Ultrasound
- Drug · Device
- Lead sponsor
- Erica Eugster
- Other
- Eligibility
- Up to 2 Weeks
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Achondroplasia
- Interventions
- Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 15 Months and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2038
- U.S. locations
- 9
- States / cities
- Oakland, California • Torrance, California • Wilmington, Delaware + 6 more
- Conditions
- Idiopathic Short Stature
- Interventions
- No treatment is given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 43 participants
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Orange, California • Columbia, Maryland
- Conditions
- Growth Hormone Deficiency
- Interventions
- easypod
- Device
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Short Stature
- Interventions
- Norditropin
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Gulf War Syndrome, Adult Growth Hormone Deficiency
- Interventions
- Recombinant human growth hormone
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Interventions
- Lonapegsomatropin, Placebo, Somatropin
- Drug · Other
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 23 Years to 80 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- NuSpin, Somatropin
- Device · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 2 Years to 14 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 11 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg, Placebo 0.015 mg/kg, Placebo 0.05mg/kg, Placebo 0.15mg/kg
- Drug
- Lead sponsor
- Aileron Therapeutics, Inc.
- Industry
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Growth Hormone Deficiency
- Interventions
- growth hormone (Nutropin)
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain Injuries, Growth Hormone Deficiency Dwarfism
- Interventions
- somatropin
- Genetic
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 4
- States / cities
- Pittsburgh, Pennsylvania • El Paso, Texas • Salt Lake City, Utah + 1 more
- Conditions
- ISS, SGA
- Interventions
- Somatrogon, Genotropin
- Drug
- Lead sponsor
- Rabin Medical Center
- Other
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Centennial, Colorado • Jacksonville, Florida + 9 more
- Conditions
- Genetic Disorder, Prader-Willi Syndrome, Growth Disorder, Idiopathic Short Stature, Healthy
- Interventions
- somatropin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Growth Hormone Disorder, Adult Growth Hormone Deficiency
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 23 Years to 79 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey